HuMAB companies Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who started this subject	6/27/2003 7:21:43 AM
From: nigel bates	Read Replies (1) of 1022

Diversa's Human Antibody Program Recognized With The Gold Innovations in Healthcare(SM) Award Friday June 27, 6:30 am ET SAN DIEGO, June 27 /PRNewswire-FirstCall/ -- Diversa Corporation (Nasdaq: DVSA - News) today announced that it was awarded the Gold ABBY at the Adaptive Business Leaders (ABL) Organization's Fifth Annual Innovations in Healthcare(SM) Awards and Event for Diversa's development of a novel, proprietary Human Antibody Program. The ABL's Technology Advisory Board awards the ABBYs annually in recognition of outstanding advancements to the field of healthcare in medical technology, biotechnology, and information technology-enhanced healthcare services. The Human Antibody Program combines Diversa's patented DirectEvolution® technologies with ultra high-throughput screening capabilities to generate a novel in vitro process for isolating fully human antibodies. Diversa has engineered its fully-synthetic library to deliver a more diverse collection of antibodies with better functional properties than traditional hybridoma, transgenic animal, and phage display technologies. This novel approach is designed to provide comprehensive antibody coverage against traditionally refractory targets in order to achieve improved therapeutic performance, higher production yields, and broad patent protection against follow-on antibodies. Diversa is currently using this platform in its collaboration with Syngenta on therapeutic antibody discovery projects. In addition, Diversa recently announced a Department of Defense award to work with the U.S. Army Medical Institute of Infectious Diseases (USAMRIID) to develop diagnostic and therapeutic antibodies against anthrax and to identify new targets associated with anthrax and plague pathology...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next